Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (noted in metadata as Insight Molecular Diagnostics Inc.) on August 27, 2018. The filing documents the results of the company's annual meeting of shareholders held on the same date. The registrant is incorporated in California and is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance actions and shareholder voting results.
Material Changes and Corporate Actions
- Equity Incentive Plan Approval: Shareholders approved a new 2018 Equity Incentive Plan reserving 5,000,000 shares of common stock for stock options, restricted stock, restricted stock units (RSUs), and stock appreciation rights (SARs).
- Authorized Share Increase: Shareholders approved an amendment to the Articles of Incorporation to increase the number of authorized common shares from 50,000,000 to 85,000,000.
- Director Elections: Seven directors were elected to serve until the next annual meeting: Ronald Andrews, William Annett, Andrew Arno, Alfred D. Kingsley, Andrew J. Last, Aditya P. Mohanty, and Cavan Redmond.
- Accountant Ratification: The appointment of OUM & Co. LLP as the independent registered public accountant for the fiscal year ending December 31, 2018, was ratified.
Shareholder Voting Results
As of the record date (July 12, 2018), there were 39,407,566 shares outstanding. 26,833,527 shares (68.1% of voting power) were represented at the meeting.
| Matter | Votes For | Votes Against | Abstentions | Broker Non-Votes |
|---|---|---|---|---|
| Election of Directors | ~24.2M (per nominee) | ~114K-126K (per nominee) | N/A | 2,509,159 |
| Ratification of Accountants | 26,788,600 | 22,175 | 22,752 | 0 |
| 2018 Equity Incentive Plan | 23,391,666 | 904,134 | 28,568 | 2,509,159 |
| Amendment of Articles (Share Increase) | 25,987,466 | 796,552 | 49,509 | 0 |
Outlook, Risks, and Unusual Items
The filing includes standard forward-looking statements disclaiming obligations to update future projections. The new Equity Incentive Plan includes specific provisions prohibiting the repricing of underwater options without shareholder approval and limiting share recycling to only cancelled or forfeited awards. No unusual financial items or specific risk factors beyond standard disclosures were detailed in this specific report.
Investor Verification Checklist
- Verify the impact of the 35,000,000 share increase in authorized capital on potential future dilution.
- Review the full text of the 2018 Equity Incentive Plan (Exhibit 99.1) to understand vesting schedules and performance goals.
- Monitor the utilization of the 5,000,000 shares reserved for the new incentive plan.
- Confirm the composition of the newly elected Board of Directors and their tenure.